Avantor Reports Q4 Earnings with Revenue Beat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Should l Buy AVTR?
Source: seekingalpha
- Earnings Highlights: Avantor reported a Q4 non-GAAP EPS of $0.22, aligning with market expectations, indicating stability in its profitability.
- Revenue Performance: The company's Q4 revenue reached $1.66 billion, a 1.8% year-over-year decline, yet it surpassed market expectations by $20 million, demonstrating resilience in a challenging environment.
- Market Reaction: Despite the slight revenue drop, Avantor's presentation at the J.P. Morgan Healthcare Conference bolstered investor confidence, potentially laying the groundwork for future growth.
- Historical Data Support: Historical financial data for Avantor shows that despite market fluctuations, the company has maintained stable profitability levels, reflecting its competitiveness in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
2 Buy
9 Hold
2 Sell
Hold
Current: 11.230
Low
8.00
Averages
12.30
High
17.00
Current: 11.230
Low
8.00
Averages
12.30
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avantor Set to Announce Q4 Earnings Expectations
- Earnings Announcement Date: Avantor (AVTR) is scheduled to release its Q4 earnings report on February 11 before the market opens, with investors keenly awaiting insights into its performance and future outlook.
- EPS Expectations: The consensus EPS estimate stands at $0.22, reflecting an 18.5% year-over-year decline, indicating potential pressure on the company's profitability which may affect investor confidence.
- Revenue Forecast: The consensus revenue estimate is $1.64 billion, down 3.0% year-over-year, highlighting challenges the company faces in a competitive market, which could lead to a slowdown in future growth.
- Historical Performance Review: Over the past two years, Avantor has only beaten EPS estimates 50% of the time and revenue estimates 25% of the time, indicating significant volatility in its performance, prompting investors to exercise caution in their evaluations.
See More
Moderna Shares Drop 10% After FDA Refusal on Flu Shot Application
- Moderna Stock Drop: Moderna's shares fell 10% after the FDA refused to review its application for the experimental flu shot mRNA-1010, prompting the company to request a meeting with the FDA to clarify the path forward, which could impact its vaccine development and market confidence.
- Humana's Earnings Miss: Despite beating profit and revenue expectations, Humana reported a fourth-quarter loss of $3.96 per share, better than the expected $4.01 loss, leading to a 6.7% drop in stock price, reflecting market concerns about its profitability.
- Generac's Resilience: Generac's stock rose nearly 6% despite missing fourth-quarter earnings expectations, as CEO Aaron Jagdfeld highlighted growth in the data center market, suggesting a potential increase in backlog from key suppliers to hyperscalers in the coming quarters.
- Mattel's Significant Decline: Mattel's adjusted earnings of 39 cents per share fell short of the expected 54 cents, resulting in a 28% drop in stock price, while its guidance for the year also disappointed, indicating serious challenges ahead for the toy manufacturer.
See More
Avantor Reports FY 2025 Results and Revival Program Initiatives
- Revival Program Launched: Avantor initiated its Revival program in Q4 2025, relaunching the VWR brand and implementing critical manufacturing and supply chain improvements aimed at enhancing company agility and market competitiveness.
- Sales Decline: Net sales for Q4 2025 were $1.664 billion, a 1.4% decrease year-over-year, with foreign currency translation positively impacting sales by 3.1% and M&A negatively impacting by 0.4%, indicating a 4.1% organic sales decline.
- Significant Net Income Drop: Net income for Q4 2025 fell to $52 million from $500 million in Q4 2024, with adjusted net income at $146 million, reflecting financial challenges during the company's transformation process.
- Cash Flow Performance: Operating cash flow for Q4 2025 was $153 million, with free cash flow at $117 million, demonstrating some cash generation capability despite losses, supporting future investments and operations.
See More
Avantor Reports Q4 Earnings with Revenue Beat
- Earnings Highlights: Avantor reported a Q4 non-GAAP EPS of $0.22, aligning with market expectations, indicating stability in its profitability.
- Revenue Performance: The company's Q4 revenue reached $1.66 billion, a 1.8% year-over-year decline, yet it surpassed market expectations by $20 million, demonstrating resilience in a challenging environment.
- Market Reaction: Despite the slight revenue drop, Avantor's presentation at the J.P. Morgan Healthcare Conference bolstered investor confidence, potentially laying the groundwork for future growth.
- Historical Data Support: Historical financial data for Avantor shows that despite market fluctuations, the company has maintained stable profitability levels, reflecting its competitiveness in the industry.
See More
Benzinga's Stock Whisper Index Highlights for the Week
- Redwire Contract: Redwire CEO Peter Cannito highlighted that the company's contract with the Department of Defense underscores its strength in space and defense technologies, which could yield strong returns for investors by 2026.
- Investor Events Preview: Redwire will participate in several investor events, including the Raymond James Institutional Investors Conference on March 2, the Morgan Stanley Technology, Media, and Telecom Conference on March 3, the DB Internet & Telecom Conference on March 10, and the New Street BCG Connectivity Conference on March 26, drawing investor attention.
- Lumen Watch: Lumen is positioned as a stock to watch due to its upcoming earnings report and multiple investor events, which could significantly impact its stock performance.
- Market Dynamics Tracking: Benzinga's weekly Stock Whisper Index provides investors with opportunities to identify undervalued and emerging stocks, assisting them in navigating information overload to uncover potential investment opportunities.
See More
Avantor Executives Under Investigation for Breach of Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether Avantor, Inc. executives breached their fiduciary duties to shareholders, with allegations that could impact corporate governance and shareholder confidence.
- False Competitive Positioning: A federal securities lawsuit claims insiders at Avantor failed to disclose that the company's competitive positioning was weaker than publicly represented, potentially leading to investor misjudgment regarding the company's prospects.
- Negative Competitive Pressures: Avantor is reportedly experiencing adverse effects from increased competition, and the failure to disclose this information may result in shareholder losses in investment decisions, affecting the company's stock performance.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact attorneys promptly to protect their rights, emphasizing the importance of participation, which could influence future shareholder litigation and corporate governance structures.
See More
Avantor Set to Announce Q4 Earnings Expectations
- Earnings Announcement Date: Avantor (AVTR) is scheduled to release its Q4 earnings report on February 11 before the market opens, with investors keenly awaiting insights into its performance and future outlook.
- EPS Expectations: The consensus EPS estimate stands at $0.22, reflecting an 18.5% year-over-year decline, indicating potential pressure on the company's profitability which may affect investor confidence.
- Revenue Forecast: The consensus revenue estimate is $1.64 billion, down 3.0% year-over-year, highlighting challenges the company faces in a competitive market, which could lead to a slowdown in future growth.
- Historical Performance Review: Over the past two years, Avantor has only beaten EPS estimates 50% of the time and revenue estimates 25% of the time, indicating significant volatility in its performance, prompting investors to exercise caution in their evaluations.
See More
Moderna Shares Drop 10% After FDA Refusal on Flu Shot Application
- Moderna Stock Drop: Moderna's shares fell 10% after the FDA refused to review its application for the experimental flu shot mRNA-1010, prompting the company to request a meeting with the FDA to clarify the path forward, which could impact its vaccine development and market confidence.
- Humana's Earnings Miss: Despite beating profit and revenue expectations, Humana reported a fourth-quarter loss of $3.96 per share, better than the expected $4.01 loss, leading to a 6.7% drop in stock price, reflecting market concerns about its profitability.
- Generac's Resilience: Generac's stock rose nearly 6% despite missing fourth-quarter earnings expectations, as CEO Aaron Jagdfeld highlighted growth in the data center market, suggesting a potential increase in backlog from key suppliers to hyperscalers in the coming quarters.
- Mattel's Significant Decline: Mattel's adjusted earnings of 39 cents per share fell short of the expected 54 cents, resulting in a 28% drop in stock price, while its guidance for the year also disappointed, indicating serious challenges ahead for the toy manufacturer.
See More
Avantor Reports FY 2025 Results and Revival Program Initiatives
- Revival Program Launched: Avantor initiated its Revival program in Q4 2025, relaunching the VWR brand and implementing critical manufacturing and supply chain improvements aimed at enhancing company agility and market competitiveness.
- Sales Decline: Net sales for Q4 2025 were $1.664 billion, a 1.4% decrease year-over-year, with foreign currency translation positively impacting sales by 3.1% and M&A negatively impacting by 0.4%, indicating a 4.1% organic sales decline.
- Significant Net Income Drop: Net income for Q4 2025 fell to $52 million from $500 million in Q4 2024, with adjusted net income at $146 million, reflecting financial challenges during the company's transformation process.
- Cash Flow Performance: Operating cash flow for Q4 2025 was $153 million, with free cash flow at $117 million, demonstrating some cash generation capability despite losses, supporting future investments and operations.
See More
Avantor Reports Q4 Earnings with Revenue Beat
- Earnings Highlights: Avantor reported a Q4 non-GAAP EPS of $0.22, aligning with market expectations, indicating stability in its profitability.
- Revenue Performance: The company's Q4 revenue reached $1.66 billion, a 1.8% year-over-year decline, yet it surpassed market expectations by $20 million, demonstrating resilience in a challenging environment.
- Market Reaction: Despite the slight revenue drop, Avantor's presentation at the J.P. Morgan Healthcare Conference bolstered investor confidence, potentially laying the groundwork for future growth.
- Historical Data Support: Historical financial data for Avantor shows that despite market fluctuations, the company has maintained stable profitability levels, reflecting its competitiveness in the industry.
See More
Benzinga's Stock Whisper Index Highlights for the Week
- Redwire Contract: Redwire CEO Peter Cannito highlighted that the company's contract with the Department of Defense underscores its strength in space and defense technologies, which could yield strong returns for investors by 2026.
- Investor Events Preview: Redwire will participate in several investor events, including the Raymond James Institutional Investors Conference on March 2, the Morgan Stanley Technology, Media, and Telecom Conference on March 3, the DB Internet & Telecom Conference on March 10, and the New Street BCG Connectivity Conference on March 26, drawing investor attention.
- Lumen Watch: Lumen is positioned as a stock to watch due to its upcoming earnings report and multiple investor events, which could significantly impact its stock performance.
- Market Dynamics Tracking: Benzinga's weekly Stock Whisper Index provides investors with opportunities to identify undervalued and emerging stocks, assisting them in navigating information overload to uncover potential investment opportunities.
See More
Avantor Executives Under Investigation for Breach of Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether Avantor, Inc. executives breached their fiduciary duties to shareholders, with allegations that could impact corporate governance and shareholder confidence.
- False Competitive Positioning: A federal securities lawsuit claims insiders at Avantor failed to disclose that the company's competitive positioning was weaker than publicly represented, potentially leading to investor misjudgment regarding the company's prospects.
- Negative Competitive Pressures: Avantor is reportedly experiencing adverse effects from increased competition, and the failure to disclose this information may result in shareholder losses in investment decisions, affecting the company's stock performance.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact attorneys promptly to protect their rights, emphasizing the importance of participation, which could influence future shareholder litigation and corporate governance structures.
See More
